hydrocortisone valerate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
corticosteroids, except prednisolone derivatives 4504 57524-89-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • hydrocortisone valerate
  • hydrocortisone pentanoate
used in treatment of atopic dermatitis; RN given refers to 11beta-isomer
  • Molecular weight: 446.58
  • Formula: C26H38O6
  • CLOGP: 4.01
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 100.90
  • ALOGS: -4.77
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.23 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK 17
kinase-selectivity-class AXL,GRK2,MAP2K6 3
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.710 Moderate 0.66
pfas-class PFAS structural alert (1 = True, 0 = False) 0
rat-kpuu-brain Rat brain Kpuu 0.036 % Moderate 0.66

Approvals:

DateAgencyCompanyOrphan
March 17, 1978 FDA RANBAXY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Post cholecystectomy syndrome 113.38 42.10 20 2605 861 90624961
Electric shock 100.01 42.10 20 2605 1702 90624120
Blood immunoglobulin A increased 99.61 42.10 19 2606 1264 90624558
Vitamin B12 increased 98.84 42.10 20 2605 1806 90624016
Glomerular filtration rate increased 96.43 42.10 20 2605 2040 90623782
Granulocyte count increased 96.22 42.10 19 2606 1515 90624307
Rheumatoid factor increased 87.65 42.10 19 2606 2392 90623430
Dactylitis 83.86 42.10 20 2605 3853 90621969
Intervertebral discitis 80.78 42.10 20 2605 4500 90621322
Throat clearing 78.82 42.10 19 2606 3828 90621994
Eyelid irritation 78.70 42.10 15 2610 993 90624829
Aspartate aminotransferase 76.71 42.10 14 2611 731 90625091
Demyelination 73.60 42.10 21 2604 8119 90617703
Joint noise 72.81 42.10 19 2606 5271 90620551
Post-traumatic stress disorder 72.60 42.10 20 2605 6808 90619014
Vitamin B12 deficiency 70.78 42.10 20 2605 7466 90618356
Blood uric acid increased 70.21 42.10 20 2605 7684 90618138
White blood cells urine positive 68.93 42.10 19 2606 6479 90619343
Cholecystitis acute 66.27 42.10 20 2605 9384 90616438
Miosis 66.11 42.10 20 2605 9464 90616358
Monocyte count increased 62.62 42.10 19 2606 9078 90616744
Spinal disorder 62.01 42.10 20 2605 11659 90614163
Temperature intolerance 61.42 42.10 20 2605 12010 90613812
Progressive multifocal leukoencephalopathy 60.08 42.10 21 2604 15634 90610188
Blood pressure systolic decreased 58.02 42.10 18 2607 9252 90616570
Vitamin D deficiency 54.02 42.10 20 2605 17536 90608286
Glycosylated haemoglobin increased 52.60 42.10 19 2606 15543 90610279
Blood test abnormal 50.58 42.10 20 2605 20932 90604890
Coordination abnormal 50.21 42.10 20 2605 21336 90604486
Therapeutic product ineffective 49.84 42.10 12 2613 2402 90623420
Aspartate aminotransferase abnormal 48.73 42.10 12 2613 2637 90623185
Neutrophil count increased 48.53 42.10 19 2606 19371 90606451
Blood glucose decreased 48.42 42.10 20 2605 23409 90602413
Multiple sclerosis 45.10 42.10 20 2605 27820 90598002
Adrenal insufficiency 43.71 42.10 20 2605 29901 90595921
Lymphadenitis 43.43 42.10 12 2613 4125 90621697
Blood urea increased 43.40 42.10 20 2605 30393 90595429
Blood pressure diastolic decreased 42.58 42.10 19 2606 26807 90599015

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 54.47 37.99 20 424 48584 42572307

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Post cholecystectomy syndrome 109.81 40.36 19 2797 833 110585650
Electric shock 95.33 40.36 19 2797 1809 110584674
Glomerular filtration rate increased 94.16 40.36 19 2797 1926 110584557
Vitamin B12 increased 93.12 40.36 19 2797 2036 110584447
Blood immunoglobulin A increased 92.10 40.36 18 2798 1550 110584933
Granulocyte count increased 87.88 40.36 18 2798 1965 110584518
Rheumatoid factor increased 83.69 40.36 18 2798 2487 110583996
Dactylitis 79.89 40.36 19 2797 4114 110582369
Eyelid irritation 78.90 40.36 15 2801 1116 110585367
Aspartate aminotransferase 74.83 40.36 14 2802 955 110585528
Throat clearing 73.87 40.36 18 2798 4315 110582168
Post-traumatic stress disorder 71.07 40.36 19 2797 6577 110579906
Joint noise 70.81 40.36 18 2798 5125 110581358
Intervertebral discitis 69.98 40.36 19 2797 6971 110579512
White blood cells urine positive 68.60 40.36 19 2797 7505 110578978
Vitamin B12 deficiency 63.15 40.36 19 2797 10036 110576447
Spinal disorder 60.27 40.36 19 2797 11709 110574774
Demyelination 60.00 40.36 18 2798 9411 110577072
Cholecystitis acute 58.62 40.36 20 2796 15762 110570721
Temperature intolerance 57.03 40.36 19 2797 13931 110572552
Monocyte count increased 53.92 40.36 18 2798 13275 110573208
Blood pressure systolic decreased 53.72 40.36 18 2798 13423 110573060
Vitamin D deficiency 51.73 40.36 19 2797 18533 110567950
Therapeutic product ineffective 50.47 40.36 12 2804 2592 110583891
Progressive multifocal leukoencephalopathy 49.69 40.36 20 2796 24936 110561547
Blood uric acid increased 48.97 40.36 19 2797 21510 110564973
Miosis 48.59 40.36 19 2797 21964 110564519
Aspartate aminotransferase abnormal 47.56 40.36 12 2804 3313 110583170
Psoriasis 46.41 40.36 34 2782 139959 110446524
Coordination abnormal 46.06 40.36 19 2797 25209 110561274
Multiple sclerosis 45.72 40.36 19 2797 25679 110560804
Glycosylated haemoglobin increased 43.83 40.36 18 2798 23601 110562882
Blood test abnormal 43.79 40.36 19 2797 28535 110557948
Blood glucose decreased 43.20 40.36 19 2797 29469 110557014

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
MeSH PA D000893 Anti-Inflammatory Agents
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:49167 anti-asthmatic drugs
CHEBI has role CHEBI:50857 anti-allergic drugs
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite
CHEBI has role CHEBI:88188 allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.48 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST CHEMBL CHEMBL

External reference:

IDSource
D02288 KEGG_DRUG
4017946 VUID
N0000179155 NUI
4017941 VANDF
4017946 VANDF
CHEBI:50865 CHEBI
CHEMBL1200562 ChEMBL_ID
C038363 MESH_SUPPLEMENTAL_RECORD_UI
DB14544 DRUGBANK_ID
68717P8FUZ UNII
DB00741 DRUGBANK_ID
27199 RXNORM
11849 MMSL
2500 MMSL
4837 MMSL
4844 MMSL
d00254 MMSL
002147 NDDF
002153 NDDF
16602005 SNOMEDCT_US
396458002 SNOMEDCT_US
51612003 SNOMEDCT_US
56423005 SNOMEDCT_US
C0063079 UMLSCUI
C0020268 UMLSCUI
5282494 PUBCHEM_CID
5754 PUBCHEM_CID
38 INN_ID
D006854 MESH_DESCRIPTOR_UI
CHEBI:17650 CHEBI
68717P8FUZ INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Hydrocortisone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0560 OINTMENT 2 mg TOPICAL ANDA 21 sections
HYDROCORTISONE VALERATE HUMAN PRESCRIPTION DRUG LABEL 1 0713-0720 CREAM 2 mg TOPICAL ANDA 18 sections
Hydrocortisone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 21695-730 CREAM 2 mg TOPICAL ANDA 22 sections
hydrocortisone valerate cream HUMAN PRESCRIPTION DRUG LABEL 1 21922-007 CREAM 2 mg TOPICAL ANDA 18 sections
Hydrocortisone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 50090-2525 CREAM 2 mg TOPICAL ANDA 22 sections
Hydrocortisone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 51672-1290 CREAM 2 mg TOPICAL ANDA 22 sections
Hydrocortisone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 51672-1292 OINTMENT 2 mg TOPICAL ANDA 22 sections
Hydrocortisone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 54868-4451 CREAM 2 mg TOPICAL ANDA 11 sections
Hydrocortisone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 54868-5251 OINTMENT 2 mg TOPICAL ANDA 11 sections
HYDROCORTISONE VALERATE HUMAN PRESCRIPTION DRUG LABEL 1 61919-010 CREAM 2 mg TOPICAL ANDA 10 sections
HYDROCORTISONE VALERATE HUMAN PRESCRIPTION DRUG LABEL 1 68180-954 CREAM 2 mg TOPICAL ANDA 18 sections
Hydrocortisone Valerate HUMAN PRESCRIPTION DRUG LABEL 1 68462-836 OINTMENT 2 mg TOPICAL ANDA 19 sections
hydrocortisone valerate cream HUMAN PRESCRIPTION DRUG LABEL 1 71335-2723 CREAM 2 mg TOPICAL ANDA 18 sections
hydrocortisone valerate cream HUMAN PRESCRIPTION DRUG LABEL 1 71335-2843 CREAM 2 mg TOPICAL ANDA 18 sections
hydrocortisone valerate cream HUMAN PRESCRIPTION DRUG LABEL 1 72162-2301 CREAM 2 mg TOPICAL ANDA 18 sections